535
Participants
Start Date
October 4, 2006
Primary Completion Date
December 11, 2009
Study Completion Date
December 11, 2009
PAR-101/OPT-80
capsules
Vancomycin
Capsules
Gadsden
Phoenix
Hot Springs
La Mesa
Modesto
Palm Springs
Rancho Mirage
San Jose
Santa Ana
Vallejo
Washington D.C.
Miami
Port Orange
Sarasota
Marietta
Savannah
Idaho Falls
Chicago
Maywood
Indianapolis
Bowling Green
Jena
New Orleans
Baltimore
Boston
West Roxbury
Detroit
Keego Harbor
Royal Oak
Minneapolis
Tupelo
Columbia
Butte
Cedar Knolls
Neptune City
The Bronx
Charlotte
Winston-Salem
Fargo
Akron
Amherst
Cleveland
Columbus
Dayton
Philadelphia
Pittsburgh
Charleston
Rapid City
Sioux Falls
San Antonio
Winchester
Seattle
Charleston
Aalst
Alast
Antwerp
Brussels
Columbia
Ghent
Kortrijk
Liège
Mons
Montigny-le-Tilleul
Wilrijk
Calgary
Edmonton
Hamilton
Toronto
Chicoutimi
Montreal
Saint-Jérôme
Sherbrooke
Trois-Rivières
Amiens
Caen
Clichy
Garches
Grenoble
Lille
Tourcoing
Tours
Valenciennes
Cologne
Düsseldorf
Frankfurt
Hanover
Hofheim am Taunus
Lübeck
Magdeburg
Regensburg
Busto Arsizio
Genova
Milan
Modena
Torino
Badalona
Barcelona
Madrid
Palma de Mallorca
Seville
Eskilstuna
Gothenburg
Örebro
Great Yarmouth
Derriford
Barnsley
Brighton
Cambridge
Edinburgh
Liege
London
Nottingham
Oxford
Oxon
Surrey
York
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY